---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Administration"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Administration. Topics: Baseline audiology before the first dose, Route and administering provider, Preparation and dilution, Storage of the diluted solution, and 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/administration"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Administration

<a id="heading-2.1.2.10.2"></a>

## 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

### Baseline audiology before the first dose

> “Prior to initiation of LEMBAZ treatment, perform a baseline comprehensive audiology evaluation (e.g., pure tone audiometry, speech recognition, tympanometry) to establish baseline hearing levels”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Week labels are illustrative. The label specifies dosing every 2 weeks, with audiology 1 to 2 weeks after the first and second dose at each dosage level.”

Source: [LEMBAZ dosing and administration guide (2026)](https://lembazrx.com/wp-content/uploads/dosing-administration-guide.pdf)

<a id="topic-2.1.2.10.2-2"></a>

### Route and administering provider

> “Administer LEMBAZ intrathecally over 1 to 2 minutes by, or under the supervision of, a healthcare provider experienced in performing lumbar punctures”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “A trained healthcare provider gives Lembaz as an injection directly into the spinal canal”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

> “LEMBAZ is for intrathecal use only (injected into the fluid around the spinal cord).”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.1.2.10.2-3"></a>

### Preparation and dilution

> “Visually inspect the solution in the vials for particulate matter and discoloration.”
> “Withdraw the required volume of LEMBAZ from the vial and discard unused contents of the vial.”
> “Dilute LEMBAZ with 0.9% Sodium Chloride Injection (preservative free) to a total administration volume of 3 mL, 5 mL, or 10 mL based on patient’s weight (see Tables 3, 4, and 5, respectively).”
> “For patients who weigh 7 kg to less than 12 kg on the LEMBAZ 600-mg dose, the LEMBAZ dose volume of 3 mL is administered undiluted.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.2-4"></a>

### Storage of the diluted solution

> “If the diluted LEMBAZ solution is not administered immediately, store it at room temperature at 20°C to 25°C (68°F to 77°F).”
> “Administer LEMBAZ within 8 hours or discard.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.2-5"></a>

### Premedication: local anesthesia and sedation

> “Consider the following concomitant therapy prior to intrathecal administration of LEMBAZ:”
> “Apply local anesthetic (topical and subcutaneous lidocaine) to the intended injection site.”
> “Consider sedation as indicated by the clinical condition of the patient.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.2-6"></a>

### Lumbar puncture technique and positioning after injection

> “If there is difficulty accessing the intrathecal space, consider imaging to guide intrathecal administration of LEMBAZ.”
> “Prior to LEMBAZ administration, remove up to 5 mL of cerebrospinal fluid (CSF).”
> “Administer LEMBAZ as an intrathecal bolus injection over 1 to 2 minutes using a spinal needle.”
> “Do not administer LEMBAZ in areas of the skin where there are signs of infection or inflammation.”
> “After administration, keep patients in the Trendelenburg position (head down at 15 to 30 degrees) for approximately 40 minutes.”
> “If unable to tolerate the Trendelenburg position, keep the patient flat as tolerated for about 40 minutes.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.2-7"></a>

### Needles and anesthesia used for repeated lumbar punctures at Rush University Medical Center

> “Intrathecal delivery of 2-hydroxypropyl-beta-cyclodextrin (VTS-270, adrabetadex) by lumbar puncture (LP) has been performed on a biweekly schedule for over nine years for the treatment of Niemann-Pick type C1 (NPC1) at Rush University Medical Center.”
> “Over this time 59 patients with NPC1 have been treated with 2935 infusions, performed with either a 22-G 3-inch Whitacre or a 22-G 2-inch Gertie Marx atraumatic needles, with or without general anesthesia.”

Source: [Albert et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37201244/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
